

**IN THE CLAIMS:**

Claims 2-5, 13, and 21 were previously canceled. Claim 9 is canceled herein. Claims 1, 8, and 10 have been amended herein. All of the pending claims are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

**Listing of the Claims:**

1. (Currently amended) A cell expressing E1A and E1B proteins of an adenovirus, said cell comprising recombinant nucleic acid comprising a selectable marker, said recombinant nucleic acid further encoding an IgA molecule in expressible format, wherein said cell is derived from a human embryonic retinoblast cell as deposited under ECACC number 96022940 by stable transfection of said human embryonic retinoblast cell with the recombinant nucleic acid encoding the IgA molecule in expressible format, ~~wherein stable transfection may be determined by selecting those transfected human embryonic retinoblast cells capable of surviving growth in a media selective for the presence of the selectable marker for a predetermined amount of time~~ wherein said cell, when seeded at  $0.5 \times 10^6$  cells/well and cultured in 6-well tissue culture plates at 37 °C in DMEM with 10%.

2.-5. (Canceled).

6. (Original) The cell of claim 1, wherein said cell comprises between one and twenty copies of said recombinant nucleic acid encoding the IgA molecule.

7. (Original) The cell of claim 1, wherein said IgA molecule is a human IgA molecule.

8. (Currently amended) A cell expressing E1A and E1B proteins of an adenovirus, said cell comprising a selectable marker, said recombinant nucleic acid further comprising recombinant nucleic acid encoding an IgA molecule in expressible format, wherein said cell is derived from a human embryonic retinoblast cell as deposited under ECACC number 96022940 by stable transfection of said human embryonic retinoblast cell with the recombinant nucleic acid encoding the IgA molecule in expressible format, and wherein said IgA molecule has a constant region comprising amino acids 137 to 489 of SEQ ID NO:3, wherein stable transfection may be determined by selecting those transfected human embryonic retinoblast cells capable of surviving growth in a media selective for the presence of the selectable marker ~~for a predetermined amount of time.~~

9. (Canceled).

10. (Currently amended) The cell of ~~claim 9~~ claim 1, wherein said cell, when seeded at  $0.5 \times 10^6$  cells/well and cultured in 6-well tissue culture plates at 37°C in DMEM with 10% serum under an atmosphere containing 10% CO<sub>2</sub>, produces at least 20 pg IgA/seeded cell/day.

11. (Previously presented) The cell of claim 10, wherein said cell, when seeded at  $0.5 \times 10^6$  cells/well and cultured in 6-well tissue culture plates at 37°C in DMEM with 10% serum under an atmosphere containing 10% CO<sub>2</sub>, produces at least 40 pg IgA/seeded cell/day.

12. (Withdrawn) A method for recombinant production of an IgA molecule, said method comprising:

culturing a cell of claim 1, and  
expressing said recombinant nucleic acid encoding an IgA molecule,  
thus producing an IgA molecule.

13. (Canceled).

14. (Withdrawn) The method according to claim 12, wherein said cell has from one to twenty copies of said recombinant nucleic acid encoding the IgA molecule.

15. (Withdrawn) The method according to claim 12, wherein said IgA molecule is a human IgA molecule.

16. (Withdrawn) The method according to claim 12, wherein said IgA molecule has a constant region comprising amino acids 137 to 489 of SEQ ID NO:3.

17. (Withdrawn) The method according to claim 12, wherein said cell is seeded at  $0.5 \times 10^6$  cells/well and cultured in 6-well tissue culture plates at 37°C in DMEM with 10% serum under an atmosphere containing 10% CO<sub>2</sub>, thus producing at least 5 pg IgA/seeded cell/day.

18. (Withdrawn) The method according to claim 12, wherein said cell is seeded at  $0.5 \times 10^6$  cells/well and cultured in 6-well tissue culture plates at 37°C in DMEM with 10% serum under an atmosphere containing 10% CO<sub>2</sub>, thus producing at least 20 pg IgA/seeded cell/day.

19. (Withdrawn) The method according to claim 12, wherein said cell is seeded at  $0.5 \times 10^6$  cells/well and cultured in 6-well tissue culture plates at 37°C in DMEM with 10% serum under an atmosphere containing 10% CO<sub>2</sub>, thus producing at least 40 pg IgA/seeded cell/day.

20. (Withdrawn) A process for recombinantly producing a human IgA molecule, said process comprising:

culturing the cell of claim 1, wherein said cell comprises recombinant nucleic acid encoding a human IgA molecule in expressible format, and

expressing said recombinant nucleic acid encoding an IgA,

thus producing a human IgA molecule.

21. (Canceled).

22. (Previously presented) A cell expressing E1A and E1B proteins of an adenovirus, said cell comprising recombinant nucleic acid encoding an IgA molecule in expressible format, wherein said cell is derived from a human embryonic retinoblast cell as deposited under ECACC number 96022940 by transfection of said human embryonic retinoblast cell with the recombinant nucleic acid encoding the IgA molecule in expressible format, wherein the cell expresses E1A and E1B proteins of an adenovirus after 3 weeks in culture.

23. (Previously presented) A cell expressing E1A and E1B proteins of an adenovirus, said cell comprising between one and about 20 copies of recombinant nucleic acid encoding an IgA molecule in expressible format, wherein said cell is derived from a human embryonic retinoblast cell as deposited under ECACC number 96022940 by transfection of said human embryonic retinoblast cell with the recombinant nucleic acid encoding the IgA molecule in expressible format, wherein the nucleic acid encoding an IgA molecule is not amplified within the cell.